Multicenter Phase II Safety and Preliminary Efficacy Study of 2 dose regimens of HepaStem in Patients with Acute on Chronic Liver Failure
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Liver cirrhosis; Liver failure
- Focus Adverse reactions
- Acronyms HEP101
- Sponsors Promethera Biosciences
- 30 Nov 2017 Planned End Date changed from 1 Sep 2018 to 1 Mar 2018.
- 30 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Mar 2018.
- 22 Sep 2017 Status changed from not yet recruiting to recruiting.